{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:26:41Z","timestamp":1759530401777,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Lung involvement is not widely recognized as a complication of auto-inflammatory diseases. We present a broad approach to diagnose a severe form of autoinflammatory syndrome in an adult male patient. A 63-year-old Caucasian male presented with recurrent episodes of high fever, interstitial lung infiltration, and pleural effusion. Laboratory tests performed during the flares revealed lymphopenia and increased levels of C-reactive protein and ferritin. Broad diagnostic research on infections, connective tissue diseases, and malignancies yielded negative results. The patient\u2019s symptoms promptly resolved upon the administration of glucocorticoids; however, they reappeared when the prednisone dose was reduced. All attempts to administer immunomodulatory and immunosuppressive medications were ineffective. During follow-up, autoinflammatory syndrome was suspected; however, no pathological variants of monogenic autoinflammatory diseases were identified by genome-exome sequencing. The patient did not respond to interleukin 1 blockade with anakinra. He died due to multi-organ failure, and his condition remained unresolved until the first reported description of vacuole, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome (VEXAS). We describe the diagnostic traps and reasoning process involved in establishing that the patient\u2019s symptoms were autoinflammatory in nature based on clinical symptoms, in addition to the proof of concept gained from genetic reevaluation and identification of pathogenic variants in the <jats:italic>UBA1<\/jats:italic> gene. The aim of this review is to increase the awareness of VEXAS among pulmonologists. Genetic screening for <jats:italic>UBA1<\/jats:italic> should be considered in patients with recurrent pneumonitis of unknown origin with elevated inflammatory markers and signs of cytopenia, especially if they require chronic steroids to control the disease. Respiratory manifestations are part of VEXAS; these may be dominant in the course of the disease and severe at presentation.<\/jats:p>","DOI":"10.3389\/fmed.2024.1340888","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:24:20Z","timestamp":1706243060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: VEXAS as an example of autoinflammatory syndrome in pulmonology clinical practice"],"prefix":"10.3389","volume":"11","author":[{"given":"Ewa","family":"Wi\u0119sik-Szewczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkadiusz","family":"Zegad\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Sobczy\u0144ska-Tomaszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelina","family":"Korzeniowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Jahnz-R\u00f3zyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S0953620523003370","DOI":"10.1016\/j.ejim.2023.09.016","article-title":"Respiratory involvement in connective tissue diseases","author":"Xanthouli","year":"2023","journal-title":"Eur J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population","volume":"329","author":"Beck","year":"2023","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"kead425","DOI":"10.1093\/rheumatology\/kead425","article-title":"Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome","author":"Maeda","year":"2023","journal-title":"Rheumatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/art.41743","article-title":"Somatic mutations in UBA1 define a distinct subset of relapsing Polychondritis patients with VEXAS syndrome","volume":"73","author":"Ferrada","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/art.41992","article-title":"VEXAS syndrome: a case series from a Single-Center cohort of Italian patients with Vasculitis","volume":"74","author":"Muratore","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard-2023-224460","article-title":"Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism","volume":"82","author":"Mascaro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1093\/rheumatology\/keab200","article-title":"A case of VEXAS syndrome manifesting as Kikuchi-Fujimoto disease, relapsing Polychondritis, venous thromboembolism and macrocytic Anaemia","volume":"60","author":"Lee","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.7326\/L21-0023","article-title":"Severe joint involvement in VEXAS syndrome: a case report","volume":"174","author":"Lacombe","year":"2021","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-021-00217-2","article-title":"VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder","volume":"10","author":"Huang","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jaci.2023.02.017","article-title":"Autoimmune manifestations in VEXAS: opportunities for integration and pitfalls to interpretation","volume":"151","author":"Bruno","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients*","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jaad.2022.10.052","article-title":"Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: a multicenter retrospective study of 59 cases","volume":"88","author":"Zakine","year":"2023","journal-title":"J Am Acad Dermatol [Internet]"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.chest.2022.10.011","article-title":"Pleuropulmonary manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome","volume":"163","author":"Borie","year":"2023","journal-title":"Chest"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00296-022-05266-2","article-title":"Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review","volume":"43","author":"Kouranloo","year":"2023","journal-title":"Rheumatol Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"107245","DOI":"10.1016\/j.rmed.2023.107245","article-title":"Pulmonary manifestations in VEXAS syndrome","volume":"213","author":"Casal Moura","year":"2023","journal-title":"Respir Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","article-title":"How to treat VEXAS-syndrome: a systematic review on effectiveness and safety of current treatment strategies","volume":"62","author":"Boyadzhieva","year":"2023","journal-title":"Rheumatol Oxf Engl"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1093\/rheumatology\/keab225","article-title":"VEXAS syndrome: still expanding the clinical phenotype","volume":"60","author":"Oganesyan","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1093\/rheumatology\/keab211","article-title":"VEXAS syndrome in a patient with previous spondyloarthritis with favorable response to intravenous immunoglobulin anti-IL17 therapy","volume":"60","author":"Magnol","year":"2021","journal-title":"Rheumatol Oxf Engl"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in Vexas syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","article-title":"A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","volume":"36","author":"Mekinian","year":"2022","journal-title":"Leukemia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/15353702231165030","article-title":"JAK inhibitors for the treatment of VEXAS syndrome","volume":"248","author":"Bindoli","year":"2023","journal-title":"Exp Biol Med Maywood NJ"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"926500","DOI":"10.3389\/fmed.2022.926500","article-title":"Development and implementation of the AIDA international registry for patients with VEXAS syndrome","volume":"9","author":"Vitale","year":"2022","journal-title":"Front Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1340888\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:24:24Z","timestamp":1706243064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1340888\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":23,"alternative-id":["10.3389\/fmed.2024.1340888"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1340888","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"article-number":"1340888"}}